Among the different known mutations, KRAS G12C (glycine 12 to cysteine) is quite prevalent and has been considered druggable.
No takes yet. Share an insight, caveat, or question.
Çağır et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: